AHA: J&J’s Invokana chases AZ’s Farxiga and Lilly’s Jardiance with phase 3 heart failure win fkansteiner Mon, 11/15/2021 – 14:54 More: AHA: J&J's Invokana chases AZ's Farxiga and Lilly's Jardiance with phase 3 heart failure win Source: fierce
read moreAHA: Eli Lilly and Boehringer Ingelheim’s Jardiance stays on its heart failure winning streak—this time in acute patients kdunleavy Mon, 11/15/2021 – 14:09 More: AHA: Eli Lilly and Boehringer Ingelheim's Jardiance stays on its heart failure winning streak—this time in
read moreThermo Fisher will build lab supply plant in North Carolina as part of $193M federal contract jkeenan Mon, 11/15/2021 – 12:33 More: Thermo Fisher will build lab supply plant in North Carolina as part of 3M federal contract Source: fierce
read moreBioMarin’s new launch Voxzogo could surprise investors and become a blockbuster brand: analyst esagonowsky Mon, 11/15/2021 – 10:27 More: BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst Source: fierce
read moreApellis’ eye med application on track for next year after FDA OKs inclusion of phase 2 data fkansteiner Mon, 11/15/2021 – 09:56 More: Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
read moreEpilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people More: NICE recommends cenobamate for treatment of adult epilepsy patients in UK Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals